- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of Testing for C Difficile in Clinical Practice
Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.
EP: 1.The Role of Testing for C Difficile in Clinical Practice
EP: 2.Utilizing Antibiotics in Treatment of C Difficile
EP: 3.Examining FMT for Patients With Recurrent C Difficile infections
EP: 4.Exploring Rebyota for Recurrent C Difficile Infections
EP: 5.Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
EP: 6.Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
EP: 7.Management of Recurrent C Difficile Infections in the Future
Video content above is prompted by the following:
- In which patients do you test for C difficile before treating?
- Does the timing of the testing influence when you start treatment?
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More
